Here are the 424B prospectus supplements from Bright Minds Biosciences Inc. (DRUG) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow DRUG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DRUG filings page.
Bright Minds Biosciences Inc. is conducting a primary public offering of 1,945,000 common shares at $90.00 per share, for gross proceeds of $175,050,000. After underwriting discounts and estimated expenses, the company expects net proceeds of about $164,372,000, and has granted underwriters a 30‑day option for up to an additional 291,750 shares.
Common shares outstanding are expected to rise to 9,732,161 (or 10,023,911 if the option is fully exercised) from 7,787,161 as of the prospectus date, meaning existing holders will be diluted. Bright Minds plans to use the funds to advance clinical trials for drug candidates in absence epilepsy, DEE, Prader‑Willi Syndrome, initiate phase 1 trials for BMB‑105, support earlier‑stage R&D programs and for general corporate purposes. The company warns that this is a high‑risk investment and highlights potential volatility, future capital needs and possible NASDAQ listing risks.
Bright Minds Biosciences Inc. has filed a preliminary prospectus supplement for a $100,000,000 public offering of common shares and, for certain large investors, pre-funded warrants to buy common shares. The pre-funded warrants are sold at the share price minus $0.001 and carry a token exercise price of $0.001 per share, are exercisable at any time, and include 4.99% or 9.99% ownership caps to limit post‑offering beneficial ownership.
The company has also granted underwriters a 30‑day option to purchase additional common shares. Net proceeds are expected to fund future clinical trials in absence epilepsy, developmental and epileptic encephalopathies, Prader‑Willi Syndrome, initiation of phase 1 trials for BMB‑105, earlier-stage research programs, and general corporate purposes. Bright Minds had 7,787,161 common shares outstanding as of the prospectus supplement date, with additional shares reserved under options, RSUs and warrants, so this financing may significantly dilute existing holders and increase share count over time.